<DOC>
	<DOC>NCT01751360</DOC>
	<brief_summary>To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.</brief_summary>
	<brief_title>SYR-472 Open-label Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator. 2. The participant can sign and date a written, informed consent form prior to the initiation of any study procedures. 1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease . 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>